Juvenile Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis [Phase 3]
Amgen's apremilast is being studied in a Phase 3 pediatric trial for active juvenile psoriatic arthritis. The study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis [Phase 3]
A Phase 3 pediatric trial evaluating Deucravacitinib (BMS-986165) for Juvenile Psoriatic Arthritis, assessing drug levels, efficacy, and saf…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis [Phase 3]
A Phase 3 clinical trial update for two IL-23/IL-12 inhibitors (ustekinumab and guselkumab) in pediatric participants with active juvenile p…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). [Phase 1]
A Phase 1 study evaluating pharmacokinetics, safety and tolerability of intravenous secukinumab in pediatric participants with Juvenile Psor…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis [Phase 3]
This is a Phase 3 open-label pharmacokinetics and safety study of bimekizumab in pediatric patients with Enthesitis-related arthritis and Ju…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab [Phase 3]
A Phase 3 trial in children with juvenile psoriatic arthritis compares subcutaneous risankizumab to adalimumab, evaluating adverse events, c…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis [Phase 3]
A Phase 3 clinical trial evaluating apremilast in children with oral ulcers associated with Behçet's disease or juvenile psoriatic arthritis…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.
Clinical trial update on long-term treatment strategies and effectiveness of secukinumab in Enthesitis-related Arthritis and Juvenile Psoria…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
A prospective observational study to evaluate the effectiveness of secukinumab in pediatric patients with active enthesitis-related arthriti…